Immunohematology Testing

Sample Requirements:

Red Cell Antibody / ABO Discrepancy Investigations:

□ 4 EDTA tubes – 7 mL

Other Abbreviated Tests (DAT / Eluate / Labor-Delivery):

□ 2 EDTA tubes – 7 mL

HDN Investigation:

- □ 2 EDTA tubes 5 mL from mother
- cord blood sample or 3 EDTA microtainers from baby

*Improperly labeled samples will not be processed.

| | Test Requested | Testing To Include the Following | |
|-----------------------|----------------------------|---|--|
| | Full Antibody ID | ABORh, Gel/PeG antibody screens, DAT, antibody ID panels, applicable chemicals used for ID, eluate, or adsorption when appropriate. | |
| lations Not Included. | ABO Discrepancy Resolution | ABORh and techniques such antibody identification, adsorption, etc used to resolve the discrepancy. | |
| | Labor / Delivery | Use for L/D patients only. Applicable antibody panels or screens, adsorptions, etc associated with request. | |
| | Antigen Type ONLY | Requested antigen typing. | |
| | Direct Antiglobulin Test | IgG and C3 DAT performed. Elution will be performed if indicated or requested by hospital. | |

Please note: ABO/Rh confirmation will be performed on all serological test requests. Additional testing required to resolve a type discrepancy will be automatically performed by IRL.

| Transfusion Recommendations N | , | nequested antigen typing. |
|-------------------------------|--------------------------|---|
| | Direct Antiglobulin Test | IgG and C3 DAT performed. Elution will be performed if indicated or requested by hospital. |
| | Elution | IgG and C3 DAT for confirmation. Eluate testing and adsorption, if applicable. |
| | HDN-Baby Workup | DAT (IgG ONLY) and eluate. Will include transfusion recommendations IF mother's specimen is submitted to the Blood Center for antibody testing. |
| | HDN-Mother Workup | Basic antibody identification. Verification of the mother's antibody results are used for interpretation in the baby's transfusion recommendations. |
| | Prenatal Workup | Brief antibody confirmation and antibody titer if indicated. |
| L | | |

| Test / Service | Explanation |
|------------------------|--|
| ABORh | A confirmation ABORh will be performed on every serological and platelet |
| | antibody workup. |
| | Additional testing or techniques performed to resolve blood type |
| Type Discrepancy | discrepancies. Antibody identification may be required to resolve certain |
| | discrepancies. |
| | A room temperature screen may be performed to determine if a cold |
| Antibody Screen | autoantibody could be interfering with routine testing. A screen using PeG |
| | enhancement will be used to determine where the antibody(ies) are reacting |
| | and if a PeG adsorption is appropriate when performing an adsorption. Antibody identification panels will routinely be performed using gel as the |
| Antibody ID Panel | primary identification method. Antibody panel cells may be used from various |
| Antibody ib Paller | vendors and with different potentiators or chemicals. |
| Large Inventory of | Rare anti-sera and RBCs are required for the IRL per standard 2.2 A/B. These |
| Rare Unlicensed | resources are available to identify rare antibodies in patients as well as |
| Anti-Sera and RBCs | antigen type donor units to transfusion. |
| | Performed on prenatal specimens with an alloantibody identified. Current |
| Antibody Titer | titer result and previously reported titer result, if applicable will be reported. |
| Autoadsorption | Autoadsorption technique used to remove autoantibody only on patients that |
| (PeG/Untreated) | have not been transfused within the last 3 months. |
| | Allogeneic or Differential adsorption techniques require the use of rare donor |
| | units with a specific phenotype. Allogeneic/Differential adsorptions are often |
| Allogeneic Adsorption | used to adsorb a panreactive antibody or to isolate multiple antibodies in |
| (ZZAP/Untreated/PeG) | recently transfused patients. The method of adsorption performed will be |
| | dependent on antibody reactivity, patient history, and tech decision. |
| RESt Adsorption | Adsorption technique using rabbit erythrocyte stroma may be performed |
| | during an antibody investigation that involved a cold autoantibody. |
| EGA Treatment of | EGA treatment gives the ability to differentiate between autoantibodies and |
| RBCs | clinically significant high-frequency antibodies. EGA treated RBCs can also be |
| | used to phenotype the patient in special AHG antigen typing tests. |
| DTT Treatment of RBCs | DTT treatment is an essential chemical used to aid in the classification of alloantibodies. Frequently used to mitigate drug interference such as |
| DTT Treatment of RBCs | Daratumumab. |
| | Test used to destroy IgM antibodies while IgG antibodies remain intact by |
| Chemical Treatment of | utilizing a specific concentration of the chemical DTT. Important to determine |
| Plasma | clinical significance of a maternal antibody and assessing HDN risk. |
| EE | Allows for differentiation of multiple antibodies, as well as aiding in the |
| Enzyme Treatment of | classification of low and high frequency antibodies. Papain, Trypsin and Ficin |
| RBCs | are available. |
| Le Neutralization | Test method that may be used during an antibody investigation to assist with |
| | confirmation of Lewis antibodies. |
| P1 Neutralization | Test method that may be used during an antibody investigation to assist with |
| | confirmation of P1 antibodies. |
| Plasma Neutralization | Test method that may be used during an antibody investigation to assist with |
| | confirmation of Chido/Rogers antibodies. |

Immunohem_Test_List Revised: 10_2024

| Test / Service | Explanation |
|--|---|
| Direct Antiglobulin Test | Each antibody ID specimen routinely receives two DAT's. One anti-IgG DAT performed in gel and one anti-C3 DAT performed in tube. An additional IgG DAT may be performed during an autoantibody investigation. |
| Super DAT | Super/enhanced DAT can be used for the diagnosis of AIHA, HDN, or a transfusion reaction when the traditional DAT is negative, but the clinician still suspects a hemolytic anemia. <i>Performed upon request only.</i> |
| Antibody Elution | Performed on samples with a positive DAT or positive autocontrol to determine if and what antibody is coating the patient's cells. |
| Retic Separation | Technique used to separate autologous cells from the transfused, donor cells for the purpose of antigen typing and confirmation of warm autoantibody. Will be performed if performing warm autoantibody confirmation or antigen typing and patient transfused in less than 3 months. |
| Sickle Cell Separation | Technique used to separate autologous cells of a sickle cell patient from the transfused, donor cells for the purpose of antigen typing and confirmation of a warm autoantibody. Will be performed if performing warm autoantibody confirmation or antigen typing and patient transfused in less than 3 months. |
| IS Crossmatch | Crossmatch test testing to ensure patient compatibility before units are |
| AHG Crossmatch | delivered. These test codes will only be used when the Blood Center is considered the Transfusion Service or provide crossmatch of record services. |
| Compatibility Check | Crossmatches may be requested by the hospital / transfusing facility to ensure patient compatibility before units are delivered by the Blood Center. (All crossmatches must be repeated by the hospital / transfusing facility.) |
| Antigen Screen with Patient Plasma | May be performed by the testing technologist in an effort to locate compatible products or verify compatibility when a patient has an antibody of undetermined specificity or in other applicable situations. |
| HGB S Negative Screen | Used to test donor units for hemoglobin S for transfusion of Sickle Cell Disease patients. |
| RBC Molecular Phenotype | The RBC Molecular Phenotype should be performed on all Warm Autoantibody, HTLA antibody, and Sickle Cell Disease patients. It provides a complete phenotype including many high and low frequency antigens. *Springfield IRL location only. |
| RHD Variant | Detects alteration in RHD gene resulting in partial or weak expression of RhD antigen. Valuable in resolving D typing discrepancy in pregnant women to accurately guide transfusion and Rh immune globulin prophylaxis. *Springfield IRL location only. |
| RHCE Variant | Detects variants in RHCE gene resulting in partial expression of C, c, E, e antigens. Useful in resolving C, c, E, e discrepancy to differentiate auto vs allo-Rh antibodies and avoid serious hemolytic transfusion reactions. *Springfield IRL location only. |
| PakLx Platelet Antibody Screen | Platelet antibody investigations will begin with this qualitative test to detect the presence or absence of HPA and HLA antibodies. Additional antibody identification testing is required and will be reflexed by IRL when an HLA antibody is detected. <i>*Springfield IRL location only.</i> |

| Test / Service | Explanation |
|---|--|
| HLA Antibody ID | Once an HLA antibody is detected in the PakLx, the HLA Antibody ID is performed to identify the antibodies present. A PRA (Percent Reactive Antibody) will be provided in the report and correlates with the ability to find compatible products. The higher the PRA, the more difficult locating compatible platelets will be. <i>*Springfield IRL location only.</i> |
| Capture - P Platelet Crossmatch | Depending on the patient's PRA, platelet crossmatching may be performed by the solid phase adherence test (Capture-P). The Capture-P test is relatively quick to perform and allows us to provide suitable products to patients in need. <i>*Springfield IRL location only.</i> |
| HLA-A, HLA-B Molecular Phenotype | The HLA molecular phenotype is performed on patients with an HLA antibody. This test is also performed on our platelet donors to build a database so HLA matched products may be provided. <i>*Springfield IRL location only.</i> |
| HPA Molecular Phenotype | The HPA molecular phenotype is performed on patients with an HPA antibody. This test is also performed on our platelet donors to build a database so HPA matched products may be provided. <i>*Springfield IRL location only.</i> |
| HLA or HPA Match / Mismatch Platelets | HLA and/or HPA matched / mismatched platelet products are available for known refractory patients. Matched or mismatched platelets will likely require several days' notice to recruit compatible donors and allow testing and processing of the product to be completed. |
| Saline Washed Red Blood Cells and Platelets | Process performed to RBC or Platelet products to remove unwanted plasma and plasma proteins, metabolic waste products, micro-aggregates and anticoagulant that may cause an adverse reaction. *Springfield IRL, St. Louis, and Davenport can wash RBCs and PLTs. *Peoria can wash PLTs Only. |
| Frozen / Deglycerolized Red Cells | Ability to freeze and deglycerolize phenotypically rare RBC units for alloimmunized patients that are difficult to locate blood for. *Springfield IRL location only. |

* If your closest IRL site does not perform a procedure mentioned above, specimens will be routed (based on order priority) to the closest ImpactLife IRL that performs the test.